îæ€çŽ¢
îæ€çŽ¢
î
EyePoint Pharmaceuticals Inc
EYPTîãŠã©ãããªã¹ãã«è¿œå
12.350USD
-0.890-6.72%
çµå€Â 05/15, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
1.04Bæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± EyePoint Pharmaceuticals Inc äŒæ¥å
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Companyâs lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Companyâs other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãEYPT
äŒç€ŸåEyePoint Pharmaceuticals Inc
äžå Žæ¥Jan 27, 2005
æé«çµå¶è²¬ä»»è
ãCEOãDuker (Jay S)
åŸæ¥å¡æ°165
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jan 27
æ¬ç€Ÿæåšå°480 Pleasant Street, Suite C400
éœåžWATERTOWN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·02472
é»è©±çªå·16179265000
ãŠã§ããµã€ãhttps://eyepointpharma.com/
äŒæ¥ã³ãŒãEYPT
äžå Žæ¥Jan 27, 2005
æé«çµå¶è²¬ä»»è
ãCEOãDuker (Jay S)
EyePoint Pharmaceuticals Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
60.00K
--
Dr. Goeran A. Ando, M.D.
Dr. Goeran A. Ando, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George Elston
Mr. George Elston
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
åçå èš³
é貚: USDæŽæ°æå»: Mon, Apr 6
é貚: USDæŽæ°æå»: Mon, Apr 6
FY2025
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
YUTIQ
1.60M
5.10%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
29.98M
95.56%
China
1.29M
4.12%
United Kingdom
100.00K
0.32%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
YUTIQ
1.60M
5.10%
æ ªäž»
æŽæ°æå»: Wed, May 13
æŽæ°æå»: Wed, May 13
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Cormorant Asset Management, LP
9.86%
Suvretta Capital Management, LLC
9.34%
BlackRock Institutional Trust Company, N.A.
6.48%
Franklin Advisers, Inc.
5.89%
Federated Hermes Global Investment Management Corp.
5.74%
ä»ã®
62.70%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Cormorant Asset Management, LP
9.86%
Suvretta Capital Management, LLC
9.34%
BlackRock Institutional Trust Company, N.A.
6.48%
Franklin Advisers, Inc.
5.89%
Federated Hermes Global Investment Management Corp.
5.74%
ä»ã®
62.70%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Hedge Fund
37.20%
Investment Advisor
29.27%
Investment Advisor/Hedge Fund
29.25%
Private Equity
3.87%
Individual Investor
3.67%
Venture Capital
2.61%
Research Firm
2.18%
Bank and Trust
1.18%
Pension Fund
0.14%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Apr 1
æŽæ°æå»: Wed, Apr 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2026Q1
381
88.53M
105.59%
-2.75M
2025Q4
363
69.86M
126.07%
--
2025Q3
373
69.94M
127.01%
+1.23K
2025Q2
381
69.95M
127.71%
-5.27M
2025Q1
371
75.32M
126.89%
-11.89M
2024Q4
359
75.24M
109.81%
+11.20M
2024Q3
343
59.71M
126.62%
+193.11K
2024Q2
330
60.06M
120.79%
+1.75M
2024Q1
313
56.72M
108.78%
+2.51M
2023Q4
268
50.21M
76.86%
+16.41M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Cormorant Asset Management, LP
8.27M
9.91%
-60.00K
-0.72%
Dec 31, 2025
Suvretta Capital Management, LLC
7.83M
9.38%
+1.63M
+26.40%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
5.43M
6.51%
+1.15M
+26.73%
Dec 31, 2025
Franklin Advisers, Inc.
4.94M
5.92%
+798.84K
+19.31%
Dec 31, 2025
Federated Hermes Global Investment Management Corp.
4.81M
5.77%
+1.23M
+34.41%
Dec 31, 2025
Adage Capital Management, L.P.
4.70M
5.63%
-859.78K
-15.46%
Dec 31, 2025
Paradigm BioCapital Advisors LP
4.19M
5.02%
+500.79K
+13.57%
Feb 17, 2026
TCG Crossover Management, LLC
3.57M
4.28%
--
--
Dec 31, 2025
Janus Henderson Investors
2.94M
3.52%
+2.94M
--
Dec 31, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Virtus LifeSci Biotech Clinical Trials ETF
1%
Simplify Health Care ETF
0.99%
State Street SPDR S&P Pharmaceuticals ETF
0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.95%
Invesco Dorsey Wright SmallCap Momentum ETF
0.36%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares Micro-Cap ETF
0.15%
iShares Health Innovation Active ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.09%
詳现ãèŠã
Virtus LifeSci Biotech Clinical Trials ETF
æ¯ç1%
Simplify Health Care ETF
æ¯ç0.99%
State Street SPDR S&P Pharmaceuticals ETF
æ¯ç0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
æ¯ç0.95%
Invesco Dorsey Wright SmallCap Momentum ETF
æ¯ç0.36%
Federated Hermes MDT Small Cap Core ETF
æ¯ç0.3%
iShares Micro-Cap ETF
æ¯ç0.15%
iShares Health Innovation Active ETF
æ¯ç0.15%
ProShares Ultra Nasdaq Biotechnology
æ¯ç0.12%
Invesco Nasdaq Biotechnology ETF
æ¯ç0.09%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Dec 08, 2020
Merger
10â1
Dec 08, 2020
Merger
10â1
Dec 08, 2020
Merger
10â1
Dec 08, 2020
Merger
10â1
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Dec 08, 2020
Merger
10â1
Dec 08, 2020
Merger
10â1
Dec 08, 2020
Merger
10â1
Dec 08, 2020
Merger
10â1
